Cure My Disease

Don't miss your cure!

 Log in / Sign up

Portable DNA reader could slash breast cancer diagnosis time in tanzania

NCT ID NCT06633276

Diagnosis Sponsor: University of Bonn Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Oct 16, 2026 · Updated 2 times

Summary

Researchers in Tanzania are testing whether a portable DNA-reading technology called nanopore sequencing can diagnose invasive breast cancer as accurately as standard lab tests, but faster and at lower cost. The study enrolls 100 patients with suspected breast cancer who are undergoing a biopsy or surgery. Scientists will compare nanopore results with standard hormone and HER2 testing, measure how long each method takes, and track patients' quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nanopore sequencing, a portable DNA-reading technology used to analyze tumor samples
What this could lead to
If nanopore sequencing matches standard lab tests, it could give patients in Tanzania faster, cheaper breast cancer diagnoses and speed up treatment planning.
What could go wrong
This is a small pilot study of 100 patients in one country, so the results may not hold up in larger or different settings. The technology may fail to produce usable results from some biopsy samples.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with suspected invasive breast cancer undergoing diagnostic workup will be offered to participate.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with suspected diagnosis of breast cancer undergoing biopsy or surgical resection after specialist consultation as per institutional guidelines * Excess fresh tumor sample * Written informed consent Exclusion Criteria: * Unable to provide informed consent * Patients who have already commenced therapy for BC (except for treatment other than biomedicine, e.g. herbal medicines)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer invasive are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer invasive

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kilimanjaro Christian Medical Centre

    RECRUITING

    Moshi, P.O. Box 3010, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.